Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AVXL · against 107 other Healthcare companies of similar size
Ranked #46 of 108 · scores higher than 40% of peers
Bars: peers in each 10-point band of the valuation score32 peers with a valuation score of 30–39, including AVXL · Click a bar to see the companies
Mainly because of its free cash flow yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | AVXL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 92 reported | -11.7% | -14.4% | 54% | 30% | |
| EBITDA yieldHigher is better · 115 reported | Not reported | -2.5% | — | — | 50% |
| Free cash flow yieldHigher is better · 81 reported | -26.3% | -15.7% | 38% | 20% | |
| Book yieldHigher is better · 96 reported | 101.1% | 70.9% | 56% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 1 | 592M ILS (≈$160M) | 99 | 84 | |
| 43 | 79M EUR (≈$87M) | 39 | 25 | |
| 44 | 6.2B THB (≈$174M) | 38 | 36 | |
| 45 | 1.5B CNY (≈$205M) | 37 | 39 | |
| 46 | 205M USD | 33 | 36 | |
| 46 | 111M USD | 33 | ||
| 46 | 186M USD | 33 | 43 | |
| 46 | 100M USD | 33 | 37 | |
| 46 | 110M USD | 33 | 38 | |
| 46 | 213M USD | 33 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score